07 March 2017



IBA Notice of Full Year 2016 Results and Conference Call


FY16 Results Conference Call to take place on 23 March 2017 at 16:00 CET

Louvain-La-Neuve, Belgium, March 07, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its audited financial results for the 2016 financial year on Thursday, 23 March 2017 at 07:00 CET.

Conference Call Information

In addition to the press release, Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a conference call and webcast, conducted in English, to present the full year results, followed by a Q&A session.

This conference call will be held on 23 March 2017 at 16:00 CET / 15:00 GMT / 11:00 EDT / 08:00 PDT and can be accessed online at:

http://arkadinemea-events.adobeconnect.com/ibafullyear2016/event/registration.html. If you would like to participate in the Q&A, please dial (PIN code 18574023#):

 

Belgium:                      +32 2 402 96 40

UK:                              +44 20 304 32 440

NL:                              +31 10 713 81 94

LU:                              +352 20 88 06 96

US:                              +1 64 67 22 49 07

FR:                              +33 1 72 00 15 10

 

The presentation will be available on IBA’s investor relations website and on https://iba-worldwide.com/content/full-year-2016-results shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Jean-Marc Bothy

Chief Strategy Officer

Soumya Chandramouli

Chief Financial Officer

+32 10 475 890

Investorrelations@iba-group.com 

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

 Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com


Back to previous page